Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
FEMS Microbiology Letters
|
February 19, 2009
Gene expression characteristics of a cystic fibrosis epidemic strain of Pseudomonas aeruginosa during biofilm and planktonic growth
Jim Manos, Jonathan Arthur, Barbara Rose, et al.
American Journal of Hematology
|
July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
Ian W Flinn, Manish Patel, Yasuhiro Oki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 5, 2018
How common is truly benign MS in a UK population?
Emma Clare Tallantyre, Paula C Major, Michael J Atherton, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 26, 2016
Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection
David A Sheridan, Behzad Hajarizadeh, Fiona I Fenwick, et al.
Plos One
|
December 27, 2014
HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer
Brenda C O'Connell, Katie O'Callaghan, Bonnie Tillotson, et al.
Molecular Cancer Therapeutics
|
December 3, 2009
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo
Mark Douglas, Alice R Lim, James R Porter, et al.
Blood
|
December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W Flinn, Susan O'Brien, Brad Kahl, et al.
American Journal of Hematology
|
August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
Susan O'Brien, Manish Patel, Brad S Kahl, et al.
Journal of Hepatology
|
April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection
Mohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
European Urology
|
March 5, 2018
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results
Mark Douglas Tyson, Tatsuki Koyama, Dan Lee, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
FEMS Microbiology Letters
|
February 19, 2009
Gene expression characteristics of a cystic fibrosis epidemic strain of Pseudomonas aeruginosa during biofilm and planktonic growth
Jim Manos, Jonathan Arthur, Barbara Rose, et al.
American Journal of Hematology
|
July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
Ian W Flinn, Manish Patel, Yasuhiro Oki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 5, 2018
How common is truly benign MS in a UK population?
Emma Clare Tallantyre, Paula C Major, Michael J Atherton, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 26, 2016
Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection
David A Sheridan, Behzad Hajarizadeh, Fiona I Fenwick, et al.
Plos One
|
December 27, 2014
HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer
Brenda C O'Connell, Katie O'Callaghan, Bonnie Tillotson, et al.
Molecular Cancer Therapeutics
|
December 3, 2009
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo
Mark Douglas, Alice R Lim, James R Porter, et al.
Blood
|
December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W Flinn, Susan O'Brien, Brad Kahl, et al.
American Journal of Hematology
|
August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
Susan O'Brien, Manish Patel, Brad S Kahl, et al.
Journal of Hepatology
|
April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection
Mohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
European Urology
|
March 5, 2018
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results
Mark Douglas Tyson, Tatsuki Koyama, Dan Lee, et al.
Page
of 5